MBChB Richard P. Bryce compensation by year
PUMA BIOTECHNOLOGY Summary Compensation Table · all 3 fiscal years held| Component | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
| Salary | $468,217 | $482,264 | $501,555 |
| Bonus | $206,015 | $221,841 | $85,264 |
| Stock awards | $547,650 | $274,824 | $630,031 |
| Option awards | $657,043 | $336,014 | $534,008 |
| Non-equity incentive | $0 | $0 | $80,249 |
| Pension and deferred compensation | $0 | $0 | — |
| All other | $14,886 | $16,196 | $17,974 |
| Total | $1,893,811 | $1,331,139 | $1,849,081 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PUMA BIOTECHNOLOGY, INC. DEF 14A filed April 26, 2021, accession 0001564590-21-020547, and prior-year filings. Open the filing on EDGAR.
How this page was built: the PUMA BIOTECHNOLOGY, INC. filed document, accession 0001564590-21-020547. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2021.
PUMA BIOTECHNOLOGY’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Alan Auerbach | President and Chief Executive Officer | $4,413,827 |
| Jeff Ludwig | Chief Commercial Officer | $3,291,813 |
| MBChB Richard P. Bryce · this page | and MFPM Former Chief Medical and Scientific Officer (7) | $1,849,081 |
| Douglas Hunt | Senior Vice President, Regulatory Affairs, Medical Writing and Project Management | $1,593,974 |
| Maximo Nougues | Chief Financial Officer | $979,147 |
The full PUMA BIOTECHNOLOGY compensation record
free company briefThis page is one person within PUMA BIOTECHNOLOGY's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the PUMA BIOTECHNOLOGY proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PUMA BIOTECHNOLOGY's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.